Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$385.73 USD

385.73
757,268

-4.47 (-1.15%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $386.10 +0.37 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for WST

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for West Pharmaceutical Services, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 854 894 763 616 439
Receivables 512 507 489 385 319
Notes Receivable 0 0 0 0 0
Inventories 435 415 378 321 236
Other Current Assets 136 103 112 52 65
Total Current Assets 1,936 1,920 1,742 1,374 1,059
Net Property & Equipment 1,413 1,158 1,058 943 839
Investments & Advances 210 205 208 215 193
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 26 66 49 16 14
Intangibles 124 126 133 142 138
Deposits & Other Assets 21 38 56 36 29
Total Assets 3,830 3,617 3,314 2,794 2,341
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 134 2 44 2 2
Accounts Payable 242 215 232 213 157
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 123 77 143 106 73
Income Taxes Payable 0 25 0 26 6
Other Current Liabilities 155 184 166 146 94
Total Current Liabilities 672 519 594 503 342
Mortgages 0 0 0 0 0
Deferred Taxes/Income 31 33 34 33 16
Convertible Debt 0 0 0 0 0
Long-Term Debt 73 207 209 253 255
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 88 80 79 89 94
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 949 932 978 939 768
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 19 19 19 19 19
Capital Surplus 120 232 249 267 273
Retained Earnings 3,523 2,988 2,457 1,847 1,549
Other Equity -144 -183 -160 -111 -150
Treasury Stock 638 371 230 168 118
Total Shareholder's Equity 2,881 2,685 2,335 1,855 1,573
Total Liabilities & Shareholder's Equity 3,830 3,617 3,314 2,794 2,341
Total Common Equity 2,881 2,685 2,335 1,855 1,573
Shares Outstanding 73.30 74.10 74.20 74.10 73.90
Book Value Per Share 39.30 36.23 31.47 25.03 21.29

Fiscal Year End for West Pharmaceutical Services, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 854 899 796 886
Receivables NA 512 519 534 513
Notes Receivable NA 0 0 0 0
Inventories NA 435 432 449 447
Other Current Assets NA 136 123 94 91
Total Current Assets NA 1,936 1,972 1,874 1,937
Net Property & Equipment NA 1,413 1,312 1,261 1,215
Investments & Advances NA 210 195 203 209
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 26 17 67 99
Intangibles NA 124 123 125 126
Deposits & Other Assets NA 21 39 40 37
Total Assets NA 3,830 3,755 3,670 3,724
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 134 55 2 2
Accounts Payable NA 242 220 218 234
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 123 106 112 66
Income Taxes Payable NA 0 0 0 59
Other Current Liabilities NA 155 137 163 158
Total Current Liabilities NA 672 534 512 535
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 31 34 36 34
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 73 152 206 206
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 84 82 83
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 949 887 923 947
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 19 19 19 19
Capital Surplus NA 120 123 158 181
Retained Earnings NA 3,523 3,416 3,255 3,114
Other Equity NA -144 -223 -184 -168
Treasury Stock NA 638 466 501 369
Total Shareholder's Equity NA 2,881 2,868 2,747 2,776
Total Liabilities & Shareholder's Equity NA 3,830 3,755 3,670 3,724
Total Common Equity 0 2,881 2,868 2,747 2,776
Shares Outstanding 73.20 73.30 73.90 73.80 74.20
Book Value Per Share 0.00 39.30 38.81 37.22 37.42